AbCellera Biologics Inc. (FRA:8QQ)

AbCellera Biologics Statistics

Total Valuation

FRA:8QQ has a market cap or net worth of EUR 893.48 million. The enterprise value is 589.44 million.

Market Cap	893.48M
Enterprise Value	589.44M

Important Dates

The next estimated earnings date is Friday, February 20, 2026.

Earnings Date	Feb 20, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	299.34M
Shares Outstanding	n/a
Shares Change (YoY)	+1.57%
Shares Change (QoQ)	+0.12%
Owned by Insiders (%)	22.92%
Owned by Institutions (%)	27.66%
Float	203.20M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	29.68
PB Ratio	1.09
P/TBV Ratio	1.20
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-4.03
EV / Sales	19.40
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-4.52

Financial Position

The company has a current ratio of 10.10, with a Debt / Equity ratio of 0.15.

Current Ratio	10.10
Quick Ratio	8.48
Debt / Equity	0.15
Debt / EBITDA	n/a
Debt / FCF	-0.93
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -16.81% and return on invested capital (ROIC) is -12.71%.

Return on Equity (ROE)	-16.81%
Return on Assets (ROA)	-10.43%
Return on Invested Capital (ROIC)	-12.71%
Return on Capital Employed (ROCE)	-17.81%
Revenue Per Employee	50,516
Profits Per Employee	-245,504
Employee Count	596
Asset Turnover	0.03
Inventory Turnover	n/a

Taxes

Income Tax	-28.34M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +17.50% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+17.50%
50-Day Moving Average	4.20
200-Day Moving Average	3.16
Relative Strength Index (RSI)	38.72
Average Volume (20 Days)	578

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	10.40

Income Statement

In the last 12 months, FRA:8QQ had revenue of EUR 30.11 million and -146.32 million in losses. Loss per share was -0.49.

Revenue	30.11M
Gross Profit	-125.70M
Operating Income	-195.41M
Pretax Income	-174.66M
Net Income	-146.32M
EBITDA	-198.30M
EBIT	-195.41M
Loss Per Share	-0.49

Balance Sheet

The company has 422.46 million in cash and 121.21 million in debt, giving a net cash position of 301.25 million.

Cash & Cash Equivalents	422.46M
Total Debt	121.21M
Net Cash	301.25M
Net Cash Per Share	n/a
Equity (Book Value)	821.65M
Book Value Per Share	2.75
Working Capital	533.83M

Cash Flow

In the last 12 months, operating cash flow was -89.11 million and capital expenditures -41.39 million, giving a free cash flow of -130.50 million.

Operating Cash Flow	-89.11M
Capital Expenditures	-41.39M
Free Cash Flow	-130.50M
FCF Per Share	n/a

Margins

Gross Margin	n/a
Operating Margin	-649.05%
Pretax Margin	-580.11%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

FRA:8QQ does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.57%
Shareholder Yield	-1.57%
Earnings Yield	-16.38%
FCF Yield	-14.61%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:8QQ has an Altman Z-Score of 1.43 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.43
Piotroski F-Score	3